Conference Coverage

Visual snow: Alarming and not uncommon


 

FROM 2021 SCOTTSDALE HEADACHE SYMPOSIUM

Limited treatment options

Unfortunately, there is little evidence on medications to treat the problem. According to Dr. Robertson, the best available evidence – from case reports – is for lamotrigine. Nearly 20% of patients achieve a partial response, and complete responses are rare.

Clinical trials are a possibility, but patients should be made aware that medications have the potential to worsen visual snow.

Nonpharmaceutical approaches include visual and mental distraction, along with manipulation of lighting at work and at home. Stress reduction may help, and Dr. Robertson may send patients with dizziness for visual vestibular therapy to work on visual motion desensitization exercises.

There are visual snow relief videos available on YouTube, which may provide temporary relief. “It’s probably similar to white noise therapy for tinnitus,” said Dr. Robertson.

Colored glass lenses may be helpful. “I’m having the best success at this point with FL-41 lenses. Some prefer amber, and others prefer the rose-tinted, just like migraine. I usually start with that,” said Dr. Robertson. Yellow lenses may help with nyctalopia.

She recommends that patients avoid consuming too much caffeine, and that they avoid stimulants, especially attention-deficit disorder (ADD) medications. “I’ve had a lot of patients worsen with ADD medication,” said Dr. Robertson. She also warns patients away from marijuana and hallucinogens.

There is a large community available for patients with visual snow, including more than 60 Facebook groups, and many YouTube videos of patients describing their experiences. There is even a visual snow simulator that neurologists can show patients to confirm what they are seeing. “It’s very validating for the patient,” said Dr. Robertson.

Dr. Charles noted the relatively few treatment options and poor understanding of the mechanisms behind the condition. “It’s incredibly frustrating that we have to tell them that we have so little understanding of basic mechanisms, and no really clear therapeutic strategy that we can apply across all patients and expect results,” said Dr. Charles.

The heightened interest in the condition does represent some hope. “It’s very much reassuring to people that, number one, we’re starting to understand it – but number two, that they’re not crazy. It’s very much validating to hear that it’s now a topic of much more rigorous investigation,” said Dr. Charles.

Dr. Robertson and Dr. Charles have no relevant financial disclosures.

Pages

Recommended Reading

Headache seen affecting some pregnancy outcomes
Migraine ICYMI
Devices for the treatment of migraine
Migraine ICYMI
Atogepant reduces migraine days: ADVANCE trial results published
Migraine ICYMI
Assessing headache severity via migraine symptoms can help predict outcomes
Migraine ICYMI
FDA okays new oral CGRP antagonist for migraine prevention
Migraine ICYMI
Pandemic survey: Forty-six percent of pediatric headache patients got worse
Migraine ICYMI
DIY nerve stimulation effective in episodic migraine
Migraine ICYMI
Largest ever review of new daily persistent headache assesses its clinical features
Migraine ICYMI
Erenumab beats topiramate for migraine in first head-to-head trial
Migraine ICYMI
Headache is a common post–COVID-19 complaint
Migraine ICYMI